Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010 Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD).
Jørgen Vestbo +2 more
exaly +6 more sources
Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients [PDF]
Respiratory Medicine, 2010 SummaryBackgroundAclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist bronchodilator currently in Phase III clinical development for the treatment of chronic obstructive pulmonary disease (COPD).
G F Joos, F Kanniess, E Garcia Gil
exaly +4 more sources
Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. [PDF]
Int J Chron Obstruct Pulmon Dis, 2018 John R Hurst,1 Maria Dilleen,2 Kevin Morris,3 Siân Hills,3 Birol Emir,4 Rupert Jones5 1UCL Respiratory, University College London, London, UK; 2Statistics, Global Product Development, Pfizer, Tadworth, UK; 3Medical Affairs, Pfizer, Tadworth, UK ...
Hurst JR +5 more
europepmc +2 more sources
International Journal of COPD, 2018 Hideyasu Yamada,1,2 Norihito Hida,2 Nobuyuki Hizawa1 1Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan; 2Department of Respiratory Medicine, Hitachinaka General Hospital, Hitachi ...
Yamada H, Hida N, Hizawa N
doaj +1 more source
Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Future Medicinal Chemistry, 2011 In 2002, the first long-acting muscarinic antagonist, tiotropium bromide (Spiriva®), was launched as a once-daily bronchodilating agent for the treatment of chronic obstructive pulmonary disease.
Jakob Busch-Petersen, Dramane I Lainé
core +3 more sources
Therapeutic effect of long-acting muscarinic antagonist for treating uncontrolled asthma assessed using impulse oscillometry [PDF]
Respiratory ResearchBackground In recent years, the incorporation of LAMAs into asthma therapy has been expected to enhance symptom control. However, a significant number of patients with asthma continue to experience poorly managed symptoms.
Hiroyuki Sugawara +3 more
doaj +2 more sources
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD. [PDF]
Pulm Ther, 2017 Introduction: Comparative data on the efficacies of long-acting muscarinic antagonist (LAMA) and long-acting ß2-agonist (LABA) combinations for the treatment of moderate-to-very-severe chronic obstructive pulmonary disease (COPD) are limited.
Sion KYJ +4 more
europepmc +2 more sources
Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD:a network meta-analysis [PDF]
Thorax, 2016 BACKGROUND: The place of long-acting β agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations in stable patients with COPD is not well defined.
Dias, Sofia, Oba, Yuji, Sarva, Siva T
core +6 more sources
Inhaled long-acting muscarinic antagonists in asthma – A narrative review [PDF]
European Journal of Internal Medicine, 2021 Long-acting muscarinic antagonists (LAMAs) have a recognised role in the management of chronic obstructive pulmonary disease. In asthma, muscarinic antagonists (both short- and long-acting) were historically considered less effective than β2-agonists; only relatively recently have studies been conducted to evaluate the efficacy of LAMAs, as add-on to ...
Papi, Alberto +5 more
openaire +7 more sources
Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
International Journal of COPD, 2017 Jieun Kang,1,* Ki Tae Kim,2,* Ji-Hyun Lee,3 Eun Kyung Kim,3 Tae-Hyung Kim,4 Kwang Ha Yoo,5 Jae Seung Lee,1 Woo Jin Kim,6 Ju Han Kim,2 Yeon-Mok Oh1 1Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan ...
Kang J +9 more
doaj +1 more source